KRAS and acute lymphoblastic leukemia: To demonstrate the difference between B-ALL and T-cell ALL (T-ALL) as confirmed by flow cytometric immunophenotyping assay, we identified a higher RAS mutation frequency in newly diagnostic B-ALL patients than that in T-ALL patients (14.7 vs 0% in KRAS; 9.3 vs 6.7% in NRAS; 0.6 vs 0% in HRAS, Figure 1C).